Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
151 hedge funds and large institutions have $157M invested in Acorda Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 42 reducing their positions, and 30 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
7% less funds holding
Funds holding: 163 → 151 (-12)
33% less call options, than puts
Call options by funds: $810K | Put options by funds: $1.2M
37% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 30
65% less capital invested
Capital invested by funds: $451M → $157M (-$294M)
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$9.9M |
| 2 |
BlackRock
New York
|
+$3.75M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.69M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.99M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.93M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$11.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.65M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$2.91M |
| 4 |
Teacher Retirement System of Texas
Austin,
Texas
|
-$2.74M |
| 5 |
SCM
Scopia Capital Management
New York
|
-$2.49M |
ACOR Hedge Fund Activity: Q3 2019 in Review
151 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2019, worth a combined $157M — down 65% from $451M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ACOR and 19 opened new positions — a net loss of 11 holders — while 42 trimmed existing stakes and 57 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $9.9M. The largest seller was State Street, cutting an estimated $11.1M.
- 151 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2019, down from 163 in Q2 2019.
- Funds reported $157M of Acorda Therapeutics stock for Q3 2019, down 65% quarter-over-quarter.
- 19 funds opened new Acorda Therapeutics positions in Q3 2019 and 30 closed out, a net change of -11 holders.
- The largest Acorda Therapeutics buyer in Q3 2019 was PFM Health Sciences, an estimated $9.9M added.
- The largest Acorda Therapeutics seller in Q3 2019 was State Street, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2019.